• +353-1-415-1241(GMT OFFICE HOURS)
  • 1-800-526-8630(US/CAN TOLL FREE)
  • 1-917-300-0470(EST OFFICE HOURS)
Global Cardiovascular Drugs Market 2012-2016 - Product Image

Global Cardiovascular Drugs Market 2012-2016

  • Published: March 2013
  • Region: Global
  • 110 pages
  • TechNavio

FEATURED COMPANIES

  • Abbott Laboratories
  • Bayer AG
  • Daiichi Sankyo Co. Ltd.
  • Forest Laboratories Inc.
  • Merck & Co. Inc.
  • Pfizer Inc.
  • MORE

TechNavio's analysts forecast the Global Cardiovascular Drugs market to decline at a CAGR of 10.47 percent over the period 2012-2016. One of the key factors affecting market growth is the over-dependency of the market on the US. The Global Cardiovascular Drugs market has also been witnessing an increase in R&D activities. However, the increase in healthcare expenditure could be one of the factors that will contribute to the growth of this market.

TechNavio's report, the Global Cardiovascular Drugs Market 2012-2016, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the EMEA and APAC regions; it covers the Global Cardiovascular Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.

The key vendors dominating this market space are AstraZeneca plc, Bristol-Myers Squibb Co., Merck & Co. Inc., Novartis AG, Pfizer Inc., and Sanofi.

The other vendors mentioned in the report are Abbott Laboratories, Forest Laboratories Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Daiichi Sankyo Co. Ltd., GlaxoSmithKline READ MORE >

1. Executive Summary
2. Introduction
3. Market Coverage
Market Overview
Product Offerings
4. Market Landscape
4.1. Global Cardiovascular Drugs Market
Market Size and Forecast
4.2. Key Product Segmentation
4.3. Five Force Analysis
5. Global Anti-hypertensive Drugs Market
Market Overview
Market Size and Forecast
6. Best Selling Anti-hypertensive Drugs
6.1. Diovan/Co-Diovan
Market Overview
Market Size and Forecast
6.2. Blopress
Market Overview
Market Size and Forecast
6.3. Benicar/Benicar HCT
Market Overview
Market Size and Forecast
6.4. Micardis/Micardis HCT
Market Overview
Market Size and Forecast
6.5. Aprovel/CoAprovel (Avapro/Avalide)
Market Overview
Market Size and Forecast
6.6. Tekturna/Rasilez
Market Overview
Market Size and Forecast
6.7. Edarbi
Market Overview
6.8. Cozaar/Hyzaar
Market Overview
Market Size and Forecast
6.9. Norvasc
Market Overview
Market Size and Forecast
6.10. Exforge/Exforge HCT
Market Overview
Market Size and Forecast
6.11. Coversyl
Market Overview
Market Size and Forecast
6.12. Seloken/Toprol-XL
Market Overview
Market Size and Forecast
7. Global Anti-dyslipidemics Drugs Market
Market Overview
Market Size and Forecast
8. Best Selling Anti-dyslipidemic Drugs
8.1. Lipitor
Market Overview
Market Size and Forecast
8.2. Crestor
Market Overview
Market Size and Forecast
8.3. Niaspan
Market Overview
Market Size and Forecast
8.4. TriCor/Trilipix
Market Overview
Market Size and Forecast
8.5. Zetia/Vytorin
Market Overview
Market Size and Forecast
8.6. Tredaptive
Market Overview
9. Global Anti-thrombotics Drugs Market
Market Overview
Market Size and Forecast
10. Best Selling Anti-thrombotic Drugs
10.1. Plavix
Market Overview
Market Size and Forecast
10.2. Lovenox
Market Overview
Market Size and Forecast
10.3. Pradaxa
Market Overview
Market Size and Forecast
10.4. Xarelto
Market Overview
10.5. Brilique/Brilinta
Market Overview
10.6. Eliquis
Market Overview
11. Drug Pipeline Analysis
12. Geographical Segmentation
13. Key Leading Countries
USA
Germany
Japan
14. Rate of Incidence and Prevalence
Dyslipidemia
Hypertension
Hypercholesterolemia
Stroke
15. Vendor Landscape
16. Buying Criteria
17. Market Challenges
18. Market Growth Drivers
19. Drivers and their Impact
20. Impact of Drivers and Challenges
21. Market Trends
22. Key Vendor Analysis
22.1. Pfizer Inc.
22.1.1. Business Overview
22.1.2. Business Segmentation
22.1.3. Key Information
22.1.4. SWOT Analysis
22.2. Bristol-Myers Squibb Co.
22.2.1. Business Overview
22.2.2. Business Segmentation
22.2.3. Key Information
22.2.4. SWOT Analysis
22.3. AstraZeneca plc
22.3.1. Business Overview
22.3.2. Business Segmentation
22.3.3. Key Information
22.3.4. SWOT Analysis
22.4. Novartis AG
22.4.1. Business Overview
22.4.2. Business Segmentation
22.4.3. Key Information
22.4.4. SWOT Analysis
22.5. Merck & Co. Inc.
22.5.1. Business Overview
22.5.2. Business Segmentation
22.5.3. Key Information
22.5.4. SWOT Analysis
22.6. Sanofi S.A.
22.6.1. Business Overview
22.6.2. Business Segmentation
22.6.3. Key Information
22.6.4. SWOT Analysis
23. Other Reports in this Series
List of Exhibits:
Exhibit 1: Global Cardiovascular Drugs Market 2012-2016 (US$ billion)
Exhibit 2: Cardiovascular Drugs by Category Segmentation
Exhibit 3: Global Cardiovascular Drugs Market by Category Segmentation 2012 (percent)
Exhibit 4: Global Cardiovascular Drugs Market by Category Segmentation 2012-2016 (US$ million)
Exhibit 5: Global Cardiovascular Drugs Market by Category Segmentation 2012-2016 (in percent)
Exhibit 6: Global Anti-hypertensive Market 2012-2016 (US$ million)
Exhibit 7: Global Sales of Diovan/Co-Diovan 2012-2016 (US$ billion )
Exhibit 8: Global Sales of Blopress/Ecard (Atacand/Atacand Plus) 2012-2016 (US$ billion)
Exhibit 9: Global Sales of Benicar/Benicar HCT 2012-2016 (US$ billion)
Exhibit 10: Global Sales of Micardis/Micardis HCT 2012-2016 (US$ billion)
Exhibit 11: Global Sales of Aprovel/CoAprovel (Avapro/Avalide) 2012-2016 (US$ billion)
Exhibit 12: Global Sales of Tekturna/Rasilez 2012-2016 (US$ million)
Exhibit 13: Global Sales of Cozaar/Hyzaar 2012-2016 (US$ million)
Exhibit 14: Global Sales of Norvasc 2012-2016 (US$ billion)
Exhibit 15: Global Sales of Exforge/Exforge HCT 2012-2016 (US$ billion)
Exhibit 16: Global Sales of Coversyl 2012-2016 (US$ million)
Exhibit 17: Global Sales of Seloken/Toprol-XL 2012-2016 (US$ million)
Exhibit 18: Global Anti-dyslipidemic Market 2012-2016 (US$ million)
Exhibit 19: Global Sales of Lipitor 2012-2016 (US$ billion)
Exhibit 20: Global Sales of Crestor 2012-2016 (US$ billion)
Exhibit 21: Global Sales of Niaspan 2012-2016 (US$ million)
Exhibit 22: Global Sales of TriCor/Trilipix 2012-2016 (US$ million)
Exhibit 23: Global Sales of Zetia 2012-2016 (US$ billion)
Exhibit 24: Global Sales of Vytorin 2012-2016 (US$ billion)
Exhibit 25: Global Anti-thrombotic Market 2012-2016 (US$ million)
Exhibit 26: Global Sales of Plavix 2012-2016(US$ billion)
Exhibit 27: Global Sales of Lovenox 2012-2016 (US$ billion)
Exhibit 28: Global Sales of Pradaxa 2012-2016 (US$ million)
Exhibit 29: Oral HDL-C-raising Pipeline Drugs
Exhibit 30: Parenteral HDL-C-raising Pipeline Drugs
Exhibit 31: Severe Hypercholesterolemia Pipeline Drugs
Exhibit 32: Anti-inflammatory Pipeline Drugs
Exhibit 33: Heart Failure Pipeline Drugs
Exhibit 34: Global Cardiovascular Drugs Market by Geographical Segmentation 2012
Exhibit 35: Prevalence of Hypertension in 2012
Exhibit 36: Prevalence of Hypercholesterolemia in 2012
Exhibit 37: Prevalence of Stroke in 2012
Exhibit 38: Global Cardiovascular Drugs Market by Vendor Segmentation 2012
Exhibit 39: Global Cardiovascular Drugs Market by Vendor Segmentation 2016
Exhibit 40: Business Segmentation of Pfizer Inc.
Exhibit 41: Business Segmentation of Bristol-Myers Squibb Co.
Exhibit 42: Business Segmentation of AstraZeneca plc
Exhibit 43: Business Segmentation of Novartis AG
Exhibit 44: Business Segmentation of Merck & Co. Inc.
Exhibit 45: Business Segmentation of Sanofi S.A.

TechNavio Announces the Publication of its Research Report - Global Cardiovascular Drugs Market 2012-2016

TechNavio recognizes the following companies as the key players in the Global Cardiovascular Drugs Market: Pfizer Inc., Bristol-Myers Squibb Co, AstraZeneca plc, Novartis AG, Merck & Co. Inc. and Sanofi S.A.

Commenting on the report, an analyst from TechNavio's Healthcare team said: ''In the last few years, the Healthcare industry has witnessed phenomenal growth in the APAC region. Emerging economies such as the APAC region, Eastern Europe, and Latin America hold vast growth potential. These regions are under-equipped to address the increase in the incidence of CVDs in the region. However, the increase in the incidence of CVDs and instances of patients frequently enduring long waits for therapeutic treatments are forcing healthcare organizations in the region to opt for cardiovascular drugs. Moreover, there has been substantial investment to initiate a significant number of projects in R&D across the developing countries. Hence, healthcare organizations in developing regions such as the APAC region and the Middle East are opting for cardiovascular drugs in accordance with the demand in specific countries. The increasing demand for cardiovascular drugs in the developing countries is boosting the growth of the Global Cardiovascular Drugs market.''

According to the report, one of the major growth factors driving the Global Cardiovascular Drugs market is the increase in the prevalence of cardiovascular patients worldwide. Therapeutic drugs are among the remedies for CVDs, and hence healthcare organizations are opting for cardiovascular drugs for treatments.

Further, the report states that one of the major challenges is the over-dependency of the market on the US, because the US holds the majority of the market share.

The report also includes a discussion on other prominent companies operating in this market, such as Abbott Laboratories, Forest Laboratories Inc., F. Hoffmann-La Roche Ltd., Bayer AG, Daiichi Sankyo Co. Ltd., GlaxoSmithKline plc, Solvay SA, Takeda Pharmaceutical Co. Ltd., and The Medicines Company.

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to a SWOT analysis of the key vendors.

- AstraZeneca plc
- Bristol-Myers Squibb Co.
- Merck & Co. Inc.
- Novartis AG
- Pfizer Inc.
- Sanofi.
- Abbott Laboratories
- Forest Laboratories Inc.
- F. Hoffmann-La Roche Ltd.
- Bayer AG
- Daiichi Sankyo Co. Ltd.
- GlaxoSmithKline plc
- Solvay SA
- Takeda Pharmaceutical Co. Ltd.
- The Medicines Co.

Note: Product cover images may vary from those shown

RELATED PRODUCTS

Our Clients

Our clients' logos